# EDGAR Filing Document

**Accession Number:** 0001699350
**File Stem:** 0001699350-26-000003
**Filing Date:** 2026-3
**Character Count:** 13323
**Document Hash:** f327019c7bfb6380e5830db108b98eb3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001699350-26-000003.hdr.sgml**: 20260302

**ACCESSION NUMBER**: 0001699350-26-000003

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260226

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260302

**DATE AS OF CHANGE**: 20260302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SHOULDER INNOVATIONS, INC.
- **CENTRAL INDEX KEY:** 0001699350
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 270538764
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42771
- **FILM NUMBER:** 26703442

**BUSINESS ADDRESS:**
- **STREET 1:** 1535 STEELE AVENUE SW, SUITE B
- **CITY:** GRAND RAPIDS
- **STATE:** MI
- **ZIP:** 49507
- **BUSINESS PHONE:** 616-566-0286

**MAIL ADDRESS:**
- **STREET 1:** 1535 STEELE AVENUE SW, SUITE B
- **CITY:** GRAND RAPIDS
- **STATE:** MI
- **ZIP:** 49507

?xml version='1.0' encoding='ASCII'? si-20260226

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

___________________________________________

**FORM 8-K**

___________________________________________

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **February 26, 2026**

___________________________________________

---

| | | |
|:---|:---|:---|
| **SHOULDER INNOVATIONS, INC.** | **SHOULDER INNOVATIONS, INC.** | **SHOULDER INNOVATIONS, INC.** |
| (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) |
| **Delaware** | **001-42771** | **27-0538764** |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| **1535 Steele Avenue SW, Suite B** <br>**Grand Rapids, Michigan** | **1535 Steele Avenue SW, Suite B** <br>**Grand Rapids, Michigan** | **49507** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(616) 294-1026**

**Not Applicable**

(Former name or former address, if changed since last report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading symbol</u> | <u>Name of each exchange on which registered</u> |
| Common Stock, $0.001 par value per share | SI | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.** |

---

*Director Resignation* 

On February 26, 2026, Geoff Pardo notified the Board of Directors ("Board") of Shoulder Innovations, Inc. (the "Company") that he will resign as a Class I director of the Board, as a member of the Compensation Committee of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board effective immediately. Mr. Pardo's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices.

 *Director Appointment*

On February 26, 2026, the Board appointed Andrew Hykes, age 53, as a Class I member of the Board and to serve as a member of the Compensation Committee, in each case effective immediately to fill the vacancy upon the resignation of Mr. Pardo. There are no arrangements or understandings between Mr. Hykes and any other persons pursuant to which he was selected as a Class I director of the Company. Mr. Hykes will receive compensation under the Company's Non-Employee Director Compensation Program, which was previously filed with the Securities and Exchange Commission (the "SEC"). Mr. Hykes will also enter into the Company's standard form of indemnification agreement for directors, which was previously filed with the SEC. Mr. Hykes does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K. The Board has determined that Mr. Hykes is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The New York Stock Exchange and the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Mr. Hykes has served as the President and Chief Executive Officer of Okami Medical, Inc., a medical device company committed to the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels ("Okami"), since October 2025. Prior to Okami, Mr. Hykes served as the Chief Executive Officer, President and director of Inari Medical, Inc., a company that provides innovative solutions for venous thromboembolism clot removal without the use of thrombolytic drugs ("Inari"), from January 2023 to May 2025. Prior to that, Mr. Hykes served as the Chief Operating Officer of Inari from October 2020 to December 2022, and as Chief Commercial Officer of Inari from September 2017 to October 2020. From November 2012 to January 2017, Mr. Hykes was the Vice President of Commercial Operations of Sequent Medical Inc., a company focused on catheter-based neurovascular therapies that was acquired by Terumo Corporation in July 2016 ("Sequent"). Prior to Sequent, Mr. Hykes worked for Medtronic PLC, a medical device company, from August 2002 to October 2012, where he held several positions of increasing responsibility, including Vice President of Marketing, Vice President of Clinical and Regulatory Affairs and Director of Investor Relations. From 1995 to 2000, Mr. Hykes worked in healthcare banking for ABN AMRO Bank. Mr. Hykes received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School.

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.** |

---

On March 2, 2026, the Company issued a press release announcing the foregoing matters, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 furnished herewith) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | | |
|:---|:---|:---|
| (d) | Exhibits: | Exhibits: |
| | 99.1 | <u>[Press Release of the Company](ex-991pressrelease2x26x2026.htm)[, dated](ex-991pressrelease2x26x2026.htm)[March 2, 2026](ex-991pressrelease2x26x2026.htm)</u><u>[.](ex-991pressrelease2x26x2026.htm)</u> |
| | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: March 2, 2026 | SHOULDER INNOVATIONS, INC.<br>(Registrant) |
| | /s/ Jeffrey Points |
| | Jeffrey Points |
| | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors**

**Grand Rapids, MI – March 2, 2026** – Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.

"Drew is a proven healthcare leader, and we are thrilled to welcome him to Shoulder Innovations as a member of our Board of Directors," said Rob Ball, CEO and Executive Chairman of Shoulder Innovations. "His strategic leadership and broad functional experience across commercial operations, product development, and business management at both Inari Medical and Medtronic will undoubtedly benefit Shoulder Innovations as we continue to rapidly scale adoption of our novel shoulder arthroplasty portfolio. On behalf of the Board, we are grateful to Geoff for his thoughtful support and guidance over the past three years and thank him for his many contributions."

"It's been a privilege serving on the Board of Shoulder Innovations and supporting the company's mission to advance shoulder surgical care," said Geoff Pardo. "I am proud of what the team has accomplished during my tenure and am confident the company is well-positioned for continued growth and innovation in the years ahead."

Mr. Hykes is a seasoned medical device executive with more than 25 years of operating experience. He currently serves as President and Chief Executive Officer of Okami Medical, a privately held medical technology company pioneering novel vascular embolization solutions. He joined Okami Medical following nearly 8 years at Inari Medical, having served most recently as Chief Executive Officer from 2023 until Inari's acquisition by Stryker Corporation in 2025. He also held the roles of Chief Operating Officer and Chief Commercial Officer during his tenure at Inari Medical. Prior, he served as Vice President of Commercial Operations at Sequent Medical, where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market, before Sequent's acquisition by Terumo Corporation. Earlier in his career, Mr. Hykes spent 11 years at Medtronic where he held multiple roles of increasing responsibility across various business units, including Vice President of Clinical and Regulatory Affairs, Vice President of Marketing, and Director of Investor Relations.

"I'm excited to join the Board of Shoulder Innovations at a pivotal stage of growth," said Drew Hykes. "The company has built a differentiated platform with strong surgeon

------

traction and meaningful clinical value. I look forward to working with the team to expand access to this technology and improve outcomes for the patients who need it most."

**About Shoulder Innovations**

Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

**Contact**

Brian Johnston or Sam Bentzinger

Gilmartin Group LLC

ir@shoulderinnovations.com

<br>